Brain metastases in breast cancer

References

• Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol. 17(6), 935–944 (2006).
   PubMed Web of Science ®Google Scholar
• Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J. Clin. Oncol. 22(17), 3608–3617 (2004).
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52(12), 2349–2354 (1983).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Smid M, Wang Y, Zhang Y et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68(9), 3108–3114 (2008).
   PubMed Web of Science ®Google Scholar
• Heitz F, Harter P, Lueck HJ et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur. J. Cancer 45(16), 2792–2798 (2009).
   PubMed Web of Science ®Google Scholar
• Bos PD, Zhang XH, Nadal C et al. Genes that mediate breast cancer metastasis to the brain. Nature 459(7249), 1005–1009 (2009).
   PubMed Web of Science ®Google Scholar
• Morris PG, Murphy CG, Mallam D et al. Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J. 18(4), 345–350 (2012).
   PubMed Web of Science ®Google Scholar
• Berghoff A, Bago-Horvath Z, De Vries C et al. Brain metastases free survival differs between breast cancer subtypes. Br. J. Cancer 106(3), 440–446 (2012).
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Mayer M, Rugo HS et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin. Cancer Res. 17(14), 4834–4843 (2011).
   PubMed Web of Science ®Google Scholar
• Arslan UY, Oksuzoglu B, Aksoy S et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast 20(6), 562–567 (2011).
   PubMed Web of Science ®Google Scholar
• Anders CK, Deal AM, Miller CR et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117(8), 1602–1611 (2011).
   PubMed Web of Science ®Google Scholar
• Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann. Oncol. 21(5), 942–948 (2010).
   PubMed Web of Science ®Google Scholar
• Kwon HC, Oh SY, Kim SH et al. Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie 33(4), 146–152 (2010).
   PubMedGoogle Scholar
• Dawood S, Gonzalez-Angulo AM, Albarracin C et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 116(13), 3084–3092 (2010).
   PubMedGoogle Scholar
• Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann. Oncol. 19(9), 1561–1565 (2008).
   PubMedGoogle Scholar
• Nam BH, Kim SY, Han HS et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 10(1), R20 (2008).
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 82(5), 2111–2117 (2012).
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30(3), 282–290 (2012).
   PubMed Web of Science ®Google Scholar
• Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 23(8), 765–776 (2012).
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28(1), 92–98 (2010).
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37(4), 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int. J. Radiat. Oncol. Biol. Phys. 70(2), 510–514 (2008).
   PubMed Web of Science ®Google Scholar
• Rades D, Lohynska R, Veninga T, Stalpers LJA, Schild SE. Evaluation of 2 whole brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer 110(11), 2587–2592 (2007).
   PubMedGoogle Scholar
• Nieder C, Marienhagen K, Astner ST, Molls M. Prognostic scores in brain metastases from breast cancer. BMC Cancer 9, 105 (2009).
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann. Neurol. 33(6), 583–590 (1993).
   PubMed Web of Science ®Google Scholar
• Murray KJ, Scott C, Greenberg HM et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int. J. Radiat. Oncol. Biol. Phys. 39(3), 571–574 (1997).
   PubMed Web of Science ®Google Scholar
• Rades D, Haatanen T, Schild SE, Dunst J. Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer 110(6), 1345–1350 (2007).
   PubMed Web of Science ®Google Scholar
• Rades D, Evers JN, Veninga T, Stalpers LJA, Lohynska R, Schild SE. Shorter-course whole-brain radiotherapy for brain metastases in elderly patients. Int. J. Radiat. Oncol. Biol. Phys. 81(4), e469–e473 (2011).
   Google Scholar
• O’Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O’Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 55(5), 1169–1176 (2003).
   PubMed Web of Science ®Google Scholar
• Rades D, Kueter JD, Pluemer A, Veninga T, Schild SE. A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 73(4), 1077–1081 (2009).
   PubMedGoogle Scholar
• Akyurek S, Chang EL, Mahajan A et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am. J. Clin. Oncol. 30(3), 310 (2007).
   PubMed Web of Science ®Google Scholar
• Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J. Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther. Onkol. 180(9), 590–596 (2004).
   PubMedGoogle Scholar
• Kased N, Binder DK, McDermott MW et al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 75(4), 1132–1140 (2009).
   PubMedGoogle Scholar
• Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21), 2483–2491 (2006).
   PubMed Web of Science ®Google Scholar
• Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J. Clin. Oncol. 29(2), 134–141 (2011).
   PubMed Web of Science ®Google Scholar
• McPherson CM, Suki D, Feiz-Erfan I et al. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro Oncol. 12(7), 711–719 (2010).
   PubMedGoogle Scholar
• Tsao MN, Lloyd N, Wong RKS et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst. Rev. 4 (2012).
   Google Scholar
• Mehta MP, Rodrigus P, Terhaard CHJ et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21(13), 2529–2536 (2003).
   PubMed Web of Science ®Google Scholar
• Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10(11), 1037–1044 (2009).
   PubMed Web of Science ®Google Scholar
• Bartsch R, Berghoff AS, Preusser M. Optimal Management of Brain Metastases from Breast Cancer. CNS Drugs 27(2), 121–134 (2013).
   PubMed Web of Science ®Google Scholar
• Lin NU, Dieras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15(4), 1452–1459 (2009).
   PubMed Web of Science ®Google Scholar
• Lin NU, Eierman W, Greil R et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J. Neuro Oncol. 105(3), 613–620 (2011).
   PubMed Web of Science ®Google Scholar
• Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann. Oncol. 22(3), 625–630 (2011).
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. (2012).
   Google Scholar
• Lin NU, Gelman RS, Younger WJ et al. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). J. Clin. Oncol. 31(15 Suppl.), Abstract 513 (2013).
   Google Scholar
• Niwinska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole, Äêbrain radiotherapy in patients with brain metastases. Cancer 116(18), 4238–4247 (2010).
   PubMed Web of Science ®Google Scholar
• Lassman AB, Abrey LE, Shah GD et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J. Neurooncol. 78(3), 255–260 (2006).
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Gabrail N, Chandhasin C et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11(2), 308–316 (2012).
   PubMed Web of Science ®Google Scholar
• Khasraw M, Robson M. Poly (ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clin. Invest. 1(11), 1545–1554 (2011).
   Google Scholar
• Mehta M, Curran W, Wang D et al. Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 84(3), S269–S270 (2012).
   Google Scholar
• Socinski MA, Langer CJ, Huang JE et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 27(31), 5255–5261 (2009).
   PubMed Web of Science ®Google Scholar
• Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 16(1), 269–278 (2010).
   PubMed Web of Science ®Google Scholar
• Levin VA, Bidaut L, Hou P et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 79(5), 1487–1495 (2011).
   PubMed Web of Science ®Google Scholar
• Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J. Clin. Oncol. 29(10), 1232–1235 (2011).
   PubMed Web of Science ®Google Scholar
• Lassman AB, Abrey LE, Shah GG et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J. Neuro Oncol. 78(3), 255–260 (2006).
   PubMed Web of Science ®Google Scholar
• Niwinska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med. Oncol. 30(1), 1–8 (2013).
   Google Scholar
• Zagouri F, Sergentanis TN, Bartsch R et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res. Treat. 139(1), 13–22 (2013).
   PubMed Web of Science ®Google Scholar
• Rivera E, Meyers C, Groves M et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107(6), 1348–1354 (2006).
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Omuro AM, Raizer JJ et al. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J. Neuro Oncol. 87(1), 85–90 (2008).
   PubMed Web of Science ®Google Scholar
• Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85(7), 1599–1605 (1999).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J. Neuro Oncol. 71(1), 61–65 (2005).
   PubMedGoogle Scholar
• Murphy C, Nulsen B, Rump M et al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiotherapy (WBXRT). 2009 Breast Cancer Symposium, Abstract 234 (2009).
   Google Scholar
• Freedman RA, Bullitt E, Sun L et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin. Breast Cancer 11(6), 376–383 (2011).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Kaufman B, Baselga J et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU). J. Clin. Oncol. 26( 15 Suppl.), Abstract 1094 (2008).
   Google Scholar
• Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br. J. Cancer 102(6), 995–1002 (2010).
   PubMedGoogle Scholar
• Bachelot TD, Romieu G, Campone M et al. LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J. Clin. Oncol. 29(Suppl.), Abstract 509 (2011).
   Google Scholar